Erythromycin Lactobionate

Inquiry

Cat Number

API3847298

CAS Number

3847-29-8

If you have any other questions, please contact our experts.

Product Detail Description Advanced Innovations Customer Q&A

CAS Number

3847-29-8

EINECS

223-348-7

Storage

2-8℃

Synonyms

Erythromycin mono(4-O-beta-D-galactopyranosyl-D-gluconate) (salt)

Molecular Formula

C49H89NO25

Molecular Weight

1092.2

Smiles

CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O.C([C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@H]([C@@H](CO)O)[C@@H]([C@H](C(=O)O)O)O)O)O)O)O

Appearance

White to off-white solid

Melting Point

145-150℃

Relative Density

0.9

General Description

Erythromycin Lactobionate is the lactobionate salt of erythromycin, a macrolide antibiotic produced by Streptomyces erythreus. The lactobionate salt form provides significantly enhanced aqueous solubility compared to erythromycin base or stearate, a property that broadens its utility in pharmaceutical research applications.

Mechanism of Action

Erythromycin exerts bacteriostatic or bactericidal activity by reversibly binding to the 50S ribosomal subunit near the peptidyl transferase center, blocking the translocation step of protein synthesis and preventing transfer of the growing polypeptide chain from the A site to the P site.

Application

Indicated for the treatment of respiratory tract infections, skin and soft tissue infections, and pelvic inflammatory disease caused by susceptible organisms. Erythromycin Lactobionate is a macrolide antibiotic with enhanced aqueous solubility suitable for parenteral administration in serious infections.

Erythromycin gelatin microspheres (EM-GMS) were successfully prepared using a double emulsion solvent evaporation method for lung-targeted delivery. The microspheres appeared spherical with smooth surfaces, a mean diameter of 15.62 μm, and over 90% ranging from 7 to 28 μm. In vitro release exhibited an initial burst (48.10% within 30 minutes) followed by sustained release. Safety evaluations showed no vein irritation, no hemolysis, and an LD50 of 173.07 mg/kg in mice. In rabbit studies, the erythromycin concentration in the lung was 15.92 times higher than in plasma, and the drug-targeting index in the lung reached 6.65 compared with erythromycin lactobionate. DSC analysis confirmed drug entrapment rather than a simple physical mixture.

Fig. 2 The surface morphology of EM-GMS (A) optical photomicrograph, (B) scanning electron micrograph. (Fan Y.; et al. 2009)

References

Fan Y, et al. Preparation and characteristics of erythromycin microspheres for lung targeting. Drug development and industrial pharmacy, 2009, 35(6): 639-645.

What distinguishes Erythromycin Lactobionate from other erythromycin salts?

Erythromycin Lactobionate offers significantly enhanced aqueous solubility compared to erythromycin base or stearate, making it the preferred form for intravenous administration in serious infections.

What storage conditions are required?

Erythromycin Lactobionate should be stored at 2-8℃ in a tightly sealed container, protected from light and moisture.

What purity grade is provided?

Supplied as a high-purity grade suitable for anti-infective R&D and pharmaceutical manufacturing.

Can order quantities and packaging be customized?

Both order quantities and packaging formats can be customized to meet specific R&D and production requirements.